Phapros Ensures Availability of Safe Multivitamins During Ramadan 2022

JAKARTA, April 4th, 2022 - PT Phapros Tbk, which is one of the national pharmaceutical companies, continues to strive to maintain the availability of its multivitamin products throughout Ramadan 2022.

Fasting during the pandemic presents its own challenges for Muslims everywhere. On the other hand, the transitional season where the cycle of rain and drought is still very fluctuating, makes the body need extra intake to fulfill its nutritional needs, especially to maintain the immune system and stamina so that fasting can continue to be healthy and fit, especially for people who have high activity levels and must remain active during this Ramadan. In line with what Phapros' CEO, Hadi Kardoko, stated that "Maintaining the immune system and as much as possible preventing the spread of Covid-19 is important during this Ramadan 2022. One way that can be done in addition to implementing strict health protocols and consuming nutritious food, is that people should also consume food supplements such as multivitamins to ensure that fasting can run smoothly and the body stays fit."

Regarding this matter, this stock-coded PEHA issuer, which has many multivitamin lines for all segments of society, whether adults, children, teenagers, or the elderly, ensures that its multivitamin product stocks are maintained and safe during Ramadan. Hadi emphasized that they have coordinated and collaborated with all stakeholders who support Phapros' business processes related to this matter.

"Our multivitamin products, such as Becefort for both adults and children, Geriavita, and Pehavral, can easily be found by the public, starting from pharmacies, retail stores, to e-commerce," he explained.

As information, one of Phapros' flagship multivitamin products, Becefort, which has been widely consumed during the pandemic, also recorded excellent performance in 2021 for e-commerce sales. The performance of this multivitamin increased by more than 100% compared to 2020.

Hadi stated that this proves that the demand for multivitamin products is still high and is also supported by a shift in consumer behavior where currently, people tend to shop via e-commerce platforms.

Previously, since the beginning of the Covid-19 pandemic, Phapros has implemented an agile, adaptive, and innovative policy strategy to continue to grow amid difficult situations like this. The policy includes shifting product portfolios from initially relying on the travel sector through one of its flagship products, Antimo, to focusing more on multivitamin products and other products related to Covid-19 prevention and treatment, optimizing all channels that can be used for performance improvement, as well as strengthening research and innovation to meet the national needs for Covid-19-related products, both promotive, preventive, and curative.

This strategy is evidenced by the launch of several new products related to Covid-19 in 2020 and 2021, such as Vitamin C Injection (Ascorin Injection), Vitamin C Effervescent (Merzavit C) through its subsidiary, PT Lucas Djaja Group, 500 mg non-acidic Vitamin C that is safe for people with gastric acid disorders, as well as Pehavit D3 1000 IU.

"We have launched several new products in 2020 and 2021, especially those related to Covid-19. In 2022, there are still around 10 new products that we will launch, both related to Covid-19 and not. For us, strengthening innovation with new products is the key to surviving and growing," concluded Hadi.